Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001376810 | SCV001573981 | pathogenic | not provided | 2023-12-22 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 125 of the CYP17A1 protein (p.Arg125Gln). This variant is present in population databases (rs104894154, gnomAD 0.004%). This missense change has been observed in individual(s) with 17-alpha-hydroxylase deficiency (PMID: 16849412, 22954317, 29858860). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 1803). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CYP17A1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects CYP17A1 function (PMID: 16849412). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV001826403 | SCV004215392 | pathogenic | Deficiency of steroid 17-alpha-monooxygenase | 2023-09-20 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000001876 | SCV000022032 | pathogenic | 17-alpha-hydroxylase/17,20-lyase deficiency, combined complete | 2006-10-01 | no assertion criteria provided | literature only | |
Natera, |
RCV001826403 | SCV002087902 | likely pathogenic | Deficiency of steroid 17-alpha-monooxygenase | 2020-08-12 | no assertion criteria provided | clinical testing |